Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX196 + Nivolumab in Hepatocellular Carcinoma
NCT03897543Phase 2Completed
- Sponsor
- Abivax
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obefazimod in hepatocellular carcinoma (HCC), sponsored by Abivax. Primary endpoint: Incidence and Severity of Adverse Events at 478 days. Started Feb 2020; status: completed.
02
Drugs
obefazimod
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03897543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897543.